NanoViricides, Inc.(NNVC)Earnings, Financials & Key Ratios

"NanoViricides remains a high-risk, pre-revenue clinical research entity characterized by a decade-long absence of commercial sales and a persistent quarterly net loss structure often exceeding $2 million. The company's reliance on equity markets to fund its $1.3 million quarterly R&D expenditure creates a structural vulnerability that threatens long-term shareholder value. Investors should monitor the firm's ability to secure non-dilutive capital, as the current cash position of approximately $1.56 million appears insufficient to sustain operations without immediate financing."